Boehringer Ingelheim acquires preclinical ADC from Aimed Bio

AstraZeneca has invested heavily in AI, primarily through collaborations, including an up to $5.3 billion partnership with China’s CSPC Pharmaceutical in June. #AI #pharma #biospace https://hubs.li/Q03Mhggr0

When Genentech moves, the industry listens — and this time, it’s not about antibodies. Starpharma just signed a collaboration and license deal with Genentech to apply its DEP dendrimer drug-delivery platform to Genentech’s oncology medicines. The numbers matter—$5.5 million upfront, up to $564 million in milestones—but the signal matters more: one of the biggest names in cancer therapeutics is betting that polymer-based conjugation can do what antibody-drug conjugates (ADCs) can’t. For years, ADCs have dominated oncology delivery. But they come with limits: toxicity, manufacturing bottlenecks, and target saturation. Dendrimer conjugates—essentially nanoscale scaffolds that fine-tune drug exposure and tolerability—offer a fresh alternative. They could extend the therapeutic index of existing small molecules, rescue shelved assets, and create new line extensions without the full risk of novel discovery. For patients, this could mean cleaner dosing and fewer hospitalizations. For payers, the test will be economic: do improved PK curves translate into measurable value? For competitors, it’s a wake-up call—enabling technologies are back in play, and delivery innovation is no longer synonymous with biologics. The broader takeaway: oncology’s next evolution may not come from new targets, but from smarter chassis. Polymer conjugates, radiotheranostics, and long-acting depots are all vying to redefine how efficacy, safety, and convenience intersect. Can dendrimer conjugates deliver proof fast enough to reshape dosing paradigms before the next wave of ADCs and radioligands takes over? 𝐑𝐞𝐚𝐝 𝐌𝐨𝐫𝐞: https://lnkd.in/dmDUk-NF #OncologyInnovation #DrugDelivery #BiotechStrategy #PharmaPartnerships #MedicalAffairs Sammi Tsegay Stephanie Edmondson

Gilead Sciences’ Recently Disclosed, Selective α4β7 Inhibitor Emvistegrast Advances to Phase 2 for UC | https://lnkd.in/dnkwDYgh Emvistegrast (GS-1427) is a selective oral α4β7 integrin inhibitor in Ph. 2 for UC, first disclosed by Gilead’s Leena Patel at the ACS Fall 2025 meeting in Washington, DC. It targets the same clinically validated pathway as vedolizumab (Entyvio®), aiming to deliver gut-selective efficacy in an orally administered drug. This ester prodrug was rationally designed from known α4β7/α4β1 dual inhibitors with picomolar potency in cellular and whole blood assays, 482-fold selectivity over α4β1, and shows on-target engagement comparable to antibody controls in multiple preclinical models. GS-1427 is now in Ph. 2 clinical trials for UC, a welcome advance for the estimated 2 million patients living with recurrent UC. Notably, this discovery story is a compelling case study in translating an antibody-targeted pathway into a small molecule approach, engineering an exceptional pharmacological profile through atropisomeric control, and optimizing ADME-PK to achieve a selective α4β7 inhibitor suitable for once-daily oral dosing. Read it on Drug Hunter: https://lnkd.in/dnkwDYgh

Biotech Stocks Positioned to Transform Treatment With Next-Gen Therapeutics (MDCX, PRTC, RANI, INO): Biotech is entering a new era of drug delivery and precision therapeutics. Dissolvable microneedles, oral biologics, DNA medicines, and next-generation small molecules are moving treatments from theory to clinic, making therapies less invasive, more targeted, and easier for patients to … Continue reading → #Business #FinancialMarket #PharmaceuticalsBiotech #US

Bristol Myers Squibb to Acquire Orbital Therapeutics for $1.5 Billion Bristol Myers Squibb stock dipped Friday following the announcement of its acquisition of private biotech company Orbital Therapeutics. Orbital is developing next-generation RNA medicines capable of reprogramming the immune system in vivo. The deal includes OTX-201, Orbital’s lead preclinical RNA immunotherapy candidate, which could enable the body to generate CAR T-cells internally—an alternative to ex vivo therapies. Robert Plenge, Chief of Research at Bristol Myers Squibb, stated the acquisition strengthens the company’s cell therapy platform and advances a potential best-in-class treatment targeting autoreactive B cells. The $1.5 billion deal is pending customary closing conditions. Until then, both companies will continue operating independently. Bristol Myers Squibb shares fell 1.54% on the news, extending an 18.08% year-to-date decline. Wall Street analysts currently rate the stock as Hold, with a price target of $50.93, representing a 15.64% upside. Read more at TipRanks https://lnkd.in/gscyEAAP

🧬 The global Monoclonal Antibodies Market is forecasted to reach a staggering $742.75 Billion by 2034, at a CAGR of 11.2%. Breakthroughs in biologics and rising demand for targeted therapies are driving market expansion. Learn more about the future of advanced therapeutics! #Biotech #Pharma #HealthcareInnovation #MonoclonalAntibodies 📊 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐑𝐞𝐩𝐨𝐫𝐭: https://lnkd.in/g9dTmarS

🚀 Life Sciences Milestone: Alchemab’s Phase I Trial Begins! Alchemab Therapeutics Ltd has launched its first-in-human Phase I trial for ATLX-1282, an AI-discovered antibody for ALS and neurodegenerative diseases. Backed by a new $32M financing round and a partnership with Eli Lilly, this marks a big step forward for AI-enabled drug discovery. A great example of how machine learning and patient data can accelerate therapies for high-need diseases. 📈🔬 👉 Read more here: https://lnkd.in/e-9NAcXG

Excited to announce our agreement with AstraZeneca to support their ADC pipeline by evaluating response mechanisms, assisting with ADC positioning, and reducing the need for large screening panels. As ADCs continue to grow in importance in the pipelines of both large and small oncology-focused pharmaceutical and biotech companies, Turbine is poised to support ADC pipelines and ensure a faster, more efficient approach towards supporting development leading to clinical benefits for patients in need. Read more here. https://lnkd.in/dEZTzzFh #turbine #rnd #drugrnd #drugdiscovery #adc

Bispecific development is rapidly advancing within South Korea. Powered by the Summit Therapeutics, Inc.'s VEGFxPD1 drug, ivonesicmab, the global bispecific market is featuring a renaissnace with South Korea establishing itself as an up and coming hub of R&D. Recent notable deals include: - Novelty Nobility Inc. partnernig with AGC Biologics to advance bispecific antibodies across Asia and Europe - https://lnkd.in/emcp2T2h - GI INNOVATION spotlights trispecific antibody pipeline designed to surpass existing PD-(L)1/VEGF bispecifics at BIO US - https://lnkd.in/eF7jGWik - Abion Inc. signs potential $800m antibody licensing deal for ABN501 which is being developed as an ADC and bispecific for CLDN3-positive tumors - https://lnkd.in/eHxBZ9e5 - Novelty Nobility Inc. joins JLABS Korea to focus development of NN4101, a bispecific antibody targeting c-Kit and VEGF - https://lnkd.in/eZ3XqSkc - ABL Bio Inc. & Yuhan Corporation advance bispecific antibodies within oncology - https://lnkd.in/e36wd_wn - ABL Bio Inc. lands $2bn deal with GSK for BBB penetrating bispecific antibody platform - https://lnkd.in/er6Mbzbn - Vaxcellbio 박셀바이오 acquire and merge with Albiotek, a company known for its bispecific antibody platform - https://lnkd.in/eN9Khdss - GC Biopharma (GC녹십자) and Kanaph Therapeutics announce joint development deal for bsADC - https://lnkd.in/eBrJpKBN I am currently conducting research into the Korean bispecific market and would love to grow my LinkedIn network in this region! If you work with or are interested in learning more about bispecific drug development and are based in Korea please drop a like, connection or a message and we can discuss in more detail. #bispecific #kddf #koreanbiopharmaceutical #bispecificantibody

Why Aarvik Therapeutics Inc Deserves Your Attention Patent WO2025194123, filed last month, exposed Aarvik's previously undisclosed target strategy. When the inventors of FDA-approved Kadcyla and Polivy, and THIOMAB site-specific conjugation (300+ patents, 20,000+ engineered antibodies) build a next-gen #ADC platform, it is worth understanding what they are targeting and why. 🟪The Strategic Play: Mucin16 × NaPi2b Bispecific ADCs🟪 With only 4% of clinical ADCs reaching FDA approval, Aarvik's modular MUTTA™ platform  seeks to address what is at the core of many of these failures - insufficient efficacy on low-expression targets: ∙ Mucin16 (CA125): Gold-standard ovarian cancer biomarker ∙ NaPi2b: 80-90% expression in epithelial ovarian cancers ∙ Complementary patterns minimise antigen escape 🟪Competitive Timing🟪 Filing as Tubulis advances NaPi2b monotherapy (TUB-040) through Phase I/2. Classic second-mover advantage - let others validate the target, then deliver superior bispecific engagement. 🟪Why This Matters🟪 This is not just one drug. MUTTA's tetravalent architecture (>100x binding improvement, bi/tri/tetravalent formats) validates a platform approach, applicable across multiple cancers and target combinations. While their ArriVent-partnered lead program ARR-002 (~$100 million in potential milestones plus royalties) remains undisclosed, this patent reveals innovative pipeline development beyond their first asset. This is the power of platform technologies: one validated approach yielding multiple shots on goal, explaining why pharma pays $10-43B for proven ADC platforms (Seagen, ImmunoGen). 🟪The Opportunity🟪 Ovarian cancer represents a $2B+ market where current ADCs have limited success. But the real prize? Proving multi-epitope targeting can finally solve ADC efficacy and off-target toxicity challenges. Founded 2020. $9.5M raised. Already delivering on the promise of capital-efficient innovation. 🟪Actionable Insights🟪 ∙ For Biopharma Strategy Leaders: Second-mover ADC strategies can capture value without first-in-class risk. Monitor patent filings for bispecific approaches to your validated targets; they signal incoming competition or partnership opportunities. ∙ For Biotech Investors: Companies with validated platform technologies, showing modular architecture across multiple formats, have lower technical risk for follow-on programs, and shorter timelines. 🟪Question for the community🟪 As ADCs evolve from single to multi-epitope targeting, which validated cancer targets are most ripe for bispecific enhancement? What combinations could unlock previously intractable indications? Information on the MUTTA™ ADC platform from Aarvik Therapeutic’s website. Patent data from Beacon ADC Patents – for more info see https://lnkd.in/d6GhqugE. #antibodydrugconjugates #bispecificADCs #drugdevelopment #competiveintelligence #biotechinnovation #patents